Abstract Library

#4643 Characterisation of patients with progressive digestive NET during PRRT (LUTA-CHEC): A multicentre study from the Groupe des Tumeurs Endocrines

Introduction: PRRT with 177Lu-DOTATATE is a major treatment for metastatic digestive NETs. Most patients have prolonged progression-free survival, but around 20% experience early progression.

Conference:

Presenting Author: Haissaguerre M

Authors: Haissaguerre M, Hadoux J, Tlili G, Deshayes E, Lacombe M,

Keywords: GEP-NET, PRRT, early tumour progression,

#4460 Digestive neuroendocrine tumours G1 and G2: Experience of the medical oncology department at the Oran University Hospital Establishment 1st November 1954

Introduction: The histological classification of neuroendocrine tumours (NETs) remains complex, and their grading is a major prognostic factor, essential for guiding appropriate management. Moreover, NETs raise unresolved histogenetic questions. The treatment of grade 1 (G1) NETs primarily relies on somatostatin analogues, while grade 2 (G2) NETs, being more heterogeneous, may require management that includes chemotherapy or targeted therapy.

Conference:

Presenting Author:

Authors: Kehili H, Bengueddache A, Boumansour N, Larbi Bounsbia L, Bechikh A,

Keywords: Digestive Neuroendocrine Tumour, Grade 1, Grade 2, Somatostatin Analogue,

#4444 Digestive neuroendocrine tumour diagnosis and therapeutic particularities: Experience of medical oncology centre Annaba, Algeria

Introduction: Neuroendocrine digestive tumours are increasingly diagnosed as a result of the rise in radiological and endoscopic procedures, improved pathological classification, and likely an increase in true incidence. All patient files must be discussed in RCP.

Conference:

Presenting Author:

Authors: Bechairia W, Djedi H,

Keywords: neuroendocrine digestive tumour, late diagnosis, multidisciplinary care,

#3990 Digestive neuroendocine tumors dignosis and therapeutic particularities: Experience of medical oncology center of Annaba, Algeria

Introduction: Digestive neuroendocrine tumors are a specific tumor entity because of its rarity they represent 1% of all digestive tumors and its heterogeneity both clinical and biological.

Conference:

Presenting Author: Bechairia W

Authors: Bechairia W,

Keywords: digestive neuroendocrine tumor, difficult diagnosis, medical treatment, benefit of multidisciplinary care,

#3874 Ileum NET lost to follow-up due to COVID-19 pandemic presents with multiple metastases and severe carcinoid syndrome

Introduction: Small bowel neuroendocrine tumors (NETs) arise from the diffuse neuroendocrine system. These are often diagnosed as a result of acute symptomatology such as bowel obstruction and are the most common cause of carcinoid syndrome (CS) due to liver metastases (LM).

Conference:

Presenting Author:

Authors: Diculescu R, Becheanu G, Croitoru A, Poiana C,

Keywords: neuroendocrine tumor, carcinoid syndrome, carcinoid heart disease, Octreotide,